Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 9,142 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Age-related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,097 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 99
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
Interventions: Trilaciclib, Placebo; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: Hepatocellular Carcinoma
Interventions: AZD5851; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more

Conditions: Healthy
Interventions: IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Plasma Cell Disorders
Interventions: Non-interventional study (observational); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Carpal Tunnel Syndrome
Interventions: Incisionless Threaded Carpal Tunnel, Standard Mini-Open Carpal Tunnel; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fecal Incontinence, Bile Acid Malabsorption
Interventions: Colesevelam, Clonidine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Brain and Central Nervous System Tumors
Interventions: carmustine, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 218
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Phenylketonuria
Interventions: Pegvaliase, Methotrexate; Biological · Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more

Conditions: Paroxysmal Hemoglobinuria, Nocturnal
Interventions: eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 14
States / cities: Stanford, California • Hartford, Connecticut • Weston, Florida + 10 more

Conditions: Olfactory Dysfunction, COVID-19
Interventions: Acupuncture Therapy, Budesonide, Olfactory Training; Device · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostatic Neoplasms
Interventions: Exisulind Therapy; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Fasting
Interventions: a breath analysis using the Aeonose, Aeonose; Other · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 879 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: MPO-ANCA Vasculitis, Microscopic Polyangiitis
Interventions: CellCept (mycophenolate mofetil); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 446
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more

Conditions: Mild Cognitive Impairment
Interventions: Aerobic & Cognitive Training (ACT), Cycling Only, Cognitive Training Only, Stretching and Mental Stimulating Activities; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 65 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • Stanford, California • Minneapolis, Minnesota + 1 more

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 14
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 10 more

Conditions: Hypotension and Shock
Interventions: Lower body negative pressure; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Cardiovascular Diseases
Interventions: Telmisartan, Combination of Telmisartan and Ramipril, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 31,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 100
States / cities: Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more

Conditions: Dry Eye Disease
Interventions: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more

Conditions: Bladder Cancer
Interventions: Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more

Search by objective public record fields.

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Ultrasound Guided - Incisionless Threaded Carpal Tunnel Release

A Study of Colesevelam in Fecal Incontinence

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Acupuncture Therapy for COVID-Related Olfactory Loss

Exisulind Prior to Radical Prostatectomy

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Electronic Nose Identification of Fasting and Non-fasting Breath Profiles

CellCept in p-ANCA Vasculitis

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial

Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

Measurement of Hemodynamic Responses to Lower Body Negative Pressure

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)